Gleiss Lutz has advised the Japanese company Daicel Corporation on the sale of its German subsidiary Lomapharm GmbH to Bionorica SE by way of an auction process. The transaction was completed on 31 March 2023.
Lomapharm is a mid-sized pharmaceutical company specialising in the manufacture of medicinal products and food supplements as well as medical devices, counting pharmaceutical groups, UN organisations and NGOs among its regular customers.
Bionorica is one of the world's leading manufacturers of herbal medicinal products. It has its registered office in Germany and its own production sites in more than ten countries. It is the market leader for phytopharmaceuticals across Germany and Eurasia.
Back in 2018, Gleiss Lutz advised Daicel Corporation on its acquisition of Lomapharm. Gleiss Lutz has a leading Japan practice, which frequently advises Japanese companies on M&A transactions.
The following Gleiss Lutz team headed by Dr. Michael Burian (lead, partner, Frankfurt) and Alexandra Brücher (both M&A, Stuttgart) advised Daicel Corporation on the transaction: Dr. Torsten Spiegel (Berlin), Ivana Robitzsch (Hamburg), Sumiko Sato (Munich, all M&A), Dr. Rut Steinhauser, (partner), Josefine Chakrabarti (counsel, both employment, Berlin), Dr. Johannes Hertfelder (partner), Rhued Gaiser (both competition/antitrust, Stuttgart), Dr. Johann Wagner (partner), Dr. Philip Niemann (both tax, Hamburg), Dr. Enno Burk (counsel, regulatory & litigation, Berlin), Dr. Alexander Nagel (counsel, Düsseldorf), Dr. Florian Kienast (Stuttgart, both restructuring), Simon Wegmann (data protection, Berlin), Dr. Christopher Noll (IP, Stuttgart).
Forward
